Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. (Q53921002)

22 May 2018

review article

1 reference

title

Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. (English)

1 reference

22 May 2018

author

Johan Burisch

2

1 reference

22 May 2018

Jean-Frédéric Colombel

5

object named as

Jean-Frédéric Colombel

1 reference

22 May 2018

author name string

Joana Torres

1

1 reference

22 May 2018

Mark Riddle

3

1 reference

22 May 2018

Marla Dubinsky

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

3 May 2016

1 reference

22 May 2018

published in

Gut

1 reference

22 May 2018

volume

65

1 reference

22 May 2018

issue

7

1 reference

22 May 2018

page(s)

1061-1069

1 reference

22 May 2018

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Epidemiology and natural history of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Long-term evolution of disease behavior of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Genetics and innate and adaptive immunity in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Exposome in IBD: recent insights in environmental factors that influence the onset and course of IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Population study of the importance of rheumatoid factor isotypes in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

When and where does inflammation begin in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Dietary glycemic index, development of islet autoimmunity, and subsequent progression to type 1 diabetes in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Incidence of rheumatoid arthritis in a genetically predisposed population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Gut virome sequencing in children with early islet autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Influenza A virus antibodies show no association with pancreatic islet autoantibodies in children genetically predisposed to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Serum 25-Hydroxyvitamin D Concentrations in Children Progressing to Autoimmunity and Clinical Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Serological markers predict inflammatory bowel disease years before the diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Increased immune reactivity predicts aggressive complicating Crohn's disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

A population-based case control study of potential risk factors for IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Clustering of increased small intestinal permeability in families with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Intestinal permeability in patients with Crohn's disease and their first degree relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Fecal calprotectin in first-degree relatives of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

P-ANCA in monozygotic twins with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Candida albicans colonization and ASCA in familial Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Subclinical inflammation with increased neutrophil activity in healthy twin siblings reflect environmental influence in the pathogenesis of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Molecular analysis of the gut microbiota of identical twins with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Removal of Bovine Insulin From Cow's Milk Formula and Early Initiation of Beta-Cell Autoimmunity in the FINDIA Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Effects of insulin in relatives of patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The maternal microbiota drives early postnatal innate immune development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Smoking and inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Appendectomy and protection against ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

The microbiome in inflammatory bowel disease: current status and the future ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Diet, the human gut microbiota, and IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Linking long-term dietary patterns with gut microbial enterotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Preclinical inflammatory rheumatic diseases: an overview and relevant nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohnʼs disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2016-311785

10.1136/GUTJNL-2016-311785

21 January 2018

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018